Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39303
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLaven-Law G.en
dc.contributor.authorMeachem S.en
dc.contributor.authorMatthiesson K.en
dc.contributor.authorMcCabe M.en
dc.contributor.authorTarulli G.en
dc.contributor.authorStanton P.en
dc.contributor.authorDinger M.en
dc.contributor.authorMcLachlan R.en
dc.date.accessioned2021-05-14T13:25:08Zen
dc.date.available2021-05-14T13:25:08Zen
dc.date.copyright2017en
dc.date.created20170209en
dc.date.issued2017-02-09en
dc.identifier.citationClinical Endocrinology. Conference: Endocrine Society of Australia Annual Scientific Meeting 2016. Gold Coast, QLD Australia. 86 (Supplement 1) (pp 32), 2017. Date of Publication: January 2017.en
dc.identifier.issn1365-2265en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/39303en
dc.description.abstractBackground: Sertoli cell tight junctions (TJs) are vital components of the blood-testis barrier that sequester adluminal meiotic germ cells and spermatids from the interstitium. In rodents, TJs are dependent upon gonadotrophin regulation for their formation at puberty and ongoing maintenance. Key TJ constituent claudin-11 is localised to the TJ near the basement membrane of seminiferous tubules during spermatogenesis. Suppressed gonadotrophins lead to the cessation of spermatogenesis and redistribution of claudin-11, resulting in dysfunctional, permeable TJs. Furthermore, the claudin-11 knockout mouse is infertile. In humans, claudin-11 is disorganised in various testicular disorders however the potential of the human TJ as a target for male hormonal contraception (MHC) is unknown. Aim(s): We aimed to investigate the localisation of claudin-11 at the human TJ following chronic gonadotrophin suppression. Method(s): Claudin-11 was assessed by immunohistochemistry in archived testis tissue with known adluminal germ cell content, from men who had undergone 8 weeks of gonadotrophin suppression. Treatments were i) testosterone enanthate (TE) plus the GnRH antagonist acyline (A); ii) T + progestin levonorgestrel (LNG); iii) TE+LNG+A or iv) TE+LNG+ 5alpha-reductase inhibitor, dutasteride. Result(s): Claudin-11 formed a continuous staining pattern at the TJ in control men. Regardless of treatment, claudin-11 localisation was markedly disrupted and broadly associated with the extent of meiotic/postmeiotic germ cell suppression; claudin-11 staining was punctate when the average numbers of adluminal germ cells were <15% of control, and fragmented or continuous when 15%-25% or >40% of control, respectively. Conclusion(s): We have demonstrated for the first time to our knowledge that claudin-11 localisation is disrupted in gonadotrophin suppressed men, consistent with its known importance in rodent spermatogenesis and fertility. We expect that a longer gonadotrophin suppression regimen would have suppressed/disrupted germ cells and claudin-11 to an even greater extent. Our findings have identified the human Sertoli cell TJ as a potential target of MHC.en
dc.languageEnglishen
dc.languageenen
dc.publisherBlackwell Publishing Ltden
dc.titleGonadotrophin suppression in men leads to a reduction in claudin-11 at the Sertoli cell tight junction. [Clinical Endocrinology]en
dc.typeConference Abstracten
dc.identifier.affiliationHudson Institute of Medical Researchen
dc.identifier.affiliationSpiritual Careen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/cen.13259en
local.date.conferencestart2016-08-21en
dc.identifier.source614326766en
dc.identifier.institution(McCabe, Dinger) Garvan Institute of Medical Research, Darlinghurst, NSW, Australia (Tarulli, Laven-Law) Discipline of Medicine, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA, Australia (Matthiesson, Meachem, McLachlan, Stanton) Hudson Institute of Medical Research, Monash Medical Centre, Clayton, VIC, Australiaen
dc.description.addressM. McCabe, Garvan Institute of Medical Research, Darlinghurst, NSW, Australiaen
dc.description.publicationstatusCONFERENCE ABSTRACTen
local.date.conferenceend2016-08-24en
dc.rights.statementCopyright 2017 Elsevier B.V., All rights reserved.en
dc.identifier.affiliationext(McCabe, Dinger) Garvan Institute of Medical Research, Darlinghurst, NSW, Australia-
dc.identifier.affiliationext(Tarulli, Laven-Law) Discipline of Medicine, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA, Australia-
dc.identifier.affiliationmh(Matthiesson, Meachem, McLachlan, Stanton) Hudson Institute of Medical Research, Monash Medical Centre, Clayton, VIC, Australia-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeConference Abstract-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptEndocrinology-
Appears in Collections:Conferences
Show simple item record

Page view(s)

6
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.